Enveric net loss narrows to $3 million in Q2 FY26; loss per share improves to $0.76
ENVB•Q2 FY26 financial results
Enveric Biosciences posted a net loss attributable to stockholders of $3 million, or $0.76 per share, for the quarter ended June 30, 2026.
Loss per share narrowed from $11.65 a year earlier. Net non-cash expense fell to $300,000 from $500,000.
EB-003 development progress
Enveric said it advanced IND-enabling work for EB-003, initiating genotoxicity studies ahead of a planned IND submission and expected Phase 1 start.
CEO Joseph Tucker cited new preclinical data supporting EB-003’s non-hallucinogenic profile, including GloSensor assay results that complement prior BRET findings.
Cash position and financing activity
Cash on hand totaled $8.3 million at quarter-end.
The company said it raised $5 million in gross proceeds in offerings and $1.5 million from warrant exercises.
